Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

Area of Science:

• Immunology
• Cancer Biology
• Pharmacology

Background:

• Ineffective T-cell responses contribute to poor anti-tumor immunity.
• Fas-FasL-dependent activation-induced cell death (AICD) of T cells compromises anti-tumor immunity.
• Regulating AICD presents a potential strategy for cancer therapy.

Purpose of the Study:

• To investigate the potential of histone deacetylase inhibitors (HDACIs) in modulating T-cell AICD for enhanced anti-tumor immunity.
• To elucidate the molecular mechanisms by which HDACIs affect T-cell apoptosis and anti-tumor responses.
• To evaluate the therapeutic potential of combining HDACIs with other immunotherapies.

Main Methods:

• Treatment of melanoma models with HDACIs.
• Analysis of CD4(+) T-cell apoptosis and FasL expression within tumors.
• Assessment of anti-tumor immune responses and tumor growth.
• Studies in gld/gld mice with FasL mutations.
• Combination therapy with HDACIs and anti-CTLA4 antibody.

Main Results:

• HDACIs inhibit AICD of CD4(+) T cells in the tumor microenvironment.
• This inhibition is mediated by suppressing NFAT1-regulated FasL expression.
• HDACIs enhance anti-tumor immune responses and suppress melanoma growth.
• The anti-tumor effect of HDACIs is dependent on FasL expression.
• Co-administration of HDACIs and anti-CTLA4 shows synergistic therapeutic effects.

Conclusions:

• HDACIs can be utilized to inhibit T-cell AICD, thereby enhancing anti-tumor immunity.
• Modulating AICD of tumor-infiltrating CD4(+) T cells is a viable strategy for cancer therapy.
• HDACIs offer a novel mechanism for improving the efficacy of cancer immunotherapy.